Efpeglenatide reduced major adverse cardiovascular events, enhanced renal outcomes, and decreased MACEs and mortality among patients with T2DM. Its efficacy and safety remain consistent with or without SGLT2 inhibitors. Efpeglenatide uniformly reduced blood pressure, body weight, low-density lipoprotein cholesterol, and urine albumin-to-creatinine ratio independent of SGLT2 inhibitor use. Here, SLC5A2 is linked to type 2 diabetes mellitus.